Kynam Capital Management, LP Viridian Therapeutics, Inc.\De Transaction History
Kynam Capital Management, LP
- $837 Million
- Q2 2025
A detailed history of Kynam Capital Management, LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Kynam Capital Management, LP holds 4,427,927 shares of VRDN stock, worth $79.6 Million. This represents 7.39% of its overall portfolio holdings.
Number of Shares
4,427,927
Previous 4,700,000
5.79%
Holding current value
$79.6 Million
Previous $63.4 Million
2.29%
% of portfolio
7.39%
Previous 5.34%
Shares
15 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
82.7MCall Options Held
78.9KPut Options Held
417K-
Deep Track Capital, LP Greenwich, CT5.38MShares$96.7 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$87.6 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$85.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$81 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$69.8 Million10.75% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $717M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...